FRACTYL HEALTH, INC. (GUTS) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings. Insiders were net buyers over the last 90 days ($39.9K bought vs $0 sold). Latest close $1.08 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Sep 14, 2026 · Congress to Nov 16, 2026.
Maverick Capital — 1 tracked fund hold GUTS. See all holders.
Insiders bought on the open market (1 purchase, $39.9K) vs 0 sales ($0). Latest buy: Sep 14, 2026. Insider trading
BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Maverick Capital | 0.03% | 3,974,806 | HELD Q3 filed Nov 16 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -89.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 75 of 8,857 filers |
| Long-only filers among them | 75 |
| Change vs 2026 Q1 | -6 net · 75 entered · 81 exited |
| Shares reported, all filers | 70,778,768 |
| Reported value, all filers | $56.1M |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus (SIC 3841) |
| Revenue · FY2025 | $0 |
| Net income · FY2025 | $-141.0M |
| Total assets · FY2025 | $121.4M |
| Shares outstanding | 159,179,848 |
| Market cap (at latest close) | $171.9M |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 4, 2026.
| Shares short · Oct 15, 2026 | 265,311 |
| Share of shares outstanding | 0.17% |
| Days to cover | 1.21 |
Shares short at recent settlements — Jul 31, 2026: 3.1M · Aug 14, 2026: 2.7M · Aug 31, 2026: 2.2M · Sep 15, 2026: 2.7M · Sep 30, 2026: 2.2M · Oct 15, 2026: 265K.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 4, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 4, 2026.
1 insider bought on the open market in the last 90 days (1 purchase, $39.9K), against 0 sales by 0 insiders ($0). Latest buy: Sep 14, 2026.
Source: SEC Form 4 filings. Open-market transactions only.
| Latest open-market buy | Transaction price | Price change since disclosure |
|---|---|---|
| BRADLEY WILLIAM · 64,516 shares on Sep 14, 2026 · filed Sep 16, 2026 | $0.62 | -86.4% (close Sep 17, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Sep 17, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | BRADLEY WILLIAM | Buy | 64,516 | $0.62 | $39.9K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Jan 30, 2025 | HARITH RAJAGOPALAN | Director, Officer | 111,920 | $226.1K | Jan 30, 2025 | SEC filing |
| Jan 30, 2025 | JAY CAPLAN | Officer | 43,818 | $88.5K | Jan 30, 2025 | SEC filing |
| Sep 12, 2024 | JAY D CAPLAN | Officer | 65,000 | $185.2K | Sep 12, 2024 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| May 15, 2026 | 683 Capital Management, LLC | SC 13G/A | 7,679,615 | 4.8% | Mar 31, 2026 | SEC filing |
| May 15, 2026 | Nantahala Capital Management, LLC | SC 13G/A | 16,124,780 | 10.0% | Mar 31, 2026 | SEC filing |
| May 13, 2026 | SilverArc Capital Management, LLC | SC 13G/A | 3,606,386 | 2.3% | Mar 31, 2026 | SEC filing |
| Feb 17, 2026 | Alyeska Investment Group, L.P. | SC 13G/A | 7,619,046 | 5.0% | Dec 31, 2025 | SEC filing |
| Feb 12, 2026 | Mithril LP | SC 13G/A | 5,160,301 | 3.8% | Dec 31, 2025 | SEC filing |
| Feb 4, 2026 | CVF, LLC | SC 13G/A | 4,673,870 | 3.4% | Feb 4, 2026 | SEC filing |
| Nov 14, 2025 | Alyeska Investment Group, L.P. | SC 13G | 13,267,417 | 9.7% | Sep 30, 2025 | SEC filing |
| Nov 14, 2025 | Nantahala Capital Management, LLC | SC 13G | 13,283,628 | 10.0% | Sep 30, 2025 | SEC filing |
| Nov 14, 2025 | SilverArc Capital Management, LLC | SC 13G | 10,600,000 | 8.0% | Sep 30, 2025 | SEC filing |
| Nov 14, 2025 | Maverick Capital, Ltd. | SC 13G/A | 4,248,492 | 3.1% | Sep 30, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Surgical & Medical Instruments & Apparatus (SIC 3841). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Insiders
· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%
Key figures
· Insider Net Buying — Buy txns: 1 · Sell txns: 0 · Buy value: $39.9K · Latest buy: Sep 14, 2026
· Distress Risk (Altman Z″) — Z″-Score: -16.47 · Working capital / assets: 0.57 · Retained earnings / assets: -4.58 · EBIT / assets: -0.80 · Equity / liabilities: 0.08
· Excess Accruals (Sloan) — Accruals ratio: -41.2% · Net income: $-141.0M · Operating cash flow: $-90.3M · Investing cash flow: $-557.0K
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 3 of the last 20 quarterly lists; latest 2026 Q2, ranked #23 of 50.
Also held by the tracked funds that hold GUTS — ranked by lift, the co-holding pattern described in Methodology: BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) · Medline Inc. (MDLN) · 3M CO (MMM) · WEST PHARMACEUTICAL SERVICES INC (WST).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 12, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Nov 6, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 22, 2026 | 2.05 Costs Associated with Exit or Disposal Activities · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
BECTON DICKINSON & CO (BDX) · Track Record: how the signals scored · Practice timing on GUTS
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.